The large majority of monoclonal antibody (mAb) therapeutics have been generated and isolated from natural immune systems, typically using mouse or rat hybridoma methods. However, the accessibility of more efficient, versatile, and high throughput methods for screening natural immune repertoires would greatly enhance current capabilities for antibody discovery: antibody discovery from alternative species, deep screening of repertoires to find rare antibodies, increased economy and speed of selections, and the ability to efficiently analyze and isolate truly human mAbs associated with infectious disease, cancer, and autoimmune conditions.
展开▼
